Haematologica, Vol 92, Issue 1, 101-105 doi:10.3324/haematol.10239
Copyright © 2007 by Ferrata Storti Foundation
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rosti, G.
Right arrow Articles by Martinelli, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rosti, G.
Right arrow Articles by Martinelli, G.

Chronic Myeloid Leukemia

Impact of age on the outcome of patients with chronic myeloid leukemia in late chronic phase: results of a phase II study of the GIMEMA CML Working Party

Gianantonio Rosti, Ilaria Iacobucci, Simona Bassi, Fausto Castagnetti, Marilina Amabile, Daniela Cilloni, Angela Poerio, Simona Soverini, Francesca Palandri, Giovanna Rege Cambrin, Franco Iuliano, Giuliana Alimena, Roberto Latagliata, Nicoletta Testoni, Fabrizio Pane, Giuseppe Saglio, Michele Baccarani, Giovanni Martinelli

From the Institute of Hematology and Medical Oncology "Seràgnoli", University of Bologna, Bologna, Italy (GR, II, FC, MA, AP, SS, FP, NT, MB, GM); Istituto Europeo di Oncologia, Milan, Italy (SB); Division of Hematology and Internal Medicine, Department of Clinical and Biological Science, University of Turin, Turin, Italy (DC, GRC, GS); Division of Hematology, Hospital "Pugliese Ciaccio", Catanzaro, Italy (FI); Division of Hematology, University "La Sapienza", Rome, Italy (GA); CEINGE Biotecnologie Avanzate and Department of Biochemistry and Medical Biotechnology, University of Naples Federico II, Naples, Italy (RL, FP)

Correspondence: Giovanni Martinelli, M.D., Molecular Biology Unit, Institute of Hematology and Medical Oncology "Seràgnoli", University of Bologna,Via Massarenti 9, 40138 Bologna, Italy. E-mail: gmartino{at}kaiser.alma.unibo.it

To assess the effect of age on response and compliance to treatment in patients with chronic myeloid leukemia (CML) we performed a sub-analysis within a phase II trial of the GIMEMA CML Working Party (CML/002/STI571). Since the WHO cut-off age to define an older patient is 65 years, among the 284 patients considered, we identified 226 (80%) younger patients (below 65 years) and 58 (20%) older patients (above 65 years) before starting imatinib. Response rates (hematologic and cytogenetic) were lower in the older age group but the probabilities of progression-free survival and overall survival (median observation time 3 years) were the same. Moreover, among complete cytogenetic responders, no differences were found in the level of molecular response between the two age groups. As might be expected, older patients experienced more adverse events, both hematologic and non-hematologic: this worsened compliance did not, however, prevent a long-term outcome similar to that of younger patients.

Key words: chronic myeloid leukemia, imatinib, older age.




This article has been cited by other articles:


Home page
 haematolHome page
H. Brenner, A. Gondos, and D. Pulte
Recent trends in long-term survival of patients with chronic myelocytic leukemia: disclosing the impact of advances in therapy on the population level
Haematologica, October 1, 2008; 93(10): 1544 - 1549.
[Abstract] [Full Text] [PDF]